Two New TRAIL Variants Without Apoptotic Potential
Author Information
Author(s): Krieg A, Krieg T, Wenzel M, Schmitt M, Ramp U, Fang B, Gabbert H E, Gerharz C D, Mahotka C
Primary Institution: Heinrich Heine-University
Hypothesis
The study investigates the existence and characteristics of two novel splice variants of TRAIL, TRAIL-β and TRAIL-γ, in human cells.
Conclusion
The novel TRAIL splice variants TRAIL-β and TRAIL-γ lack proapoptotic potential due to significant truncation of their extracellular binding domains.
Supporting Evidence
- TRAIL-β and TRAIL-γ were identified in both neoplastic and non-neoplastic cells.
- TRAIL-β and TRAIL-γ showed significant truncation of their extracellular domains.
- TRAIL-α was the only variant that induced apoptosis in HeLa cells.
Takeaway
Scientists found two new versions of a protein called TRAIL that don't help cells die like they should, which could change how we understand cancer treatment.
Methodology
The study involved RT-PCR analysis of RCC cell lines and PBMCs to identify TRAIL splice variants, followed by transfection experiments to assess apoptotic potential.
Limitations
The study primarily focused on human cells and did not explore the implications of these variants in murine models.
Participant Demographics
The study used RCC cell lines from various histological types and PBMCs from four healthy donors.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website